BioCentury | Jan 17, 2020
Translation in Brief

CPSF3 emerges as new synthetic lethality target in AML and sarcoma

A team led by the Novartis Institutes for BioMedical Research identified CPSF3, a pre-mRNA processing endonuclease, as a novel synthetic lethality target for a subset of AML and sarcomas. The premise of synthetic lethality is...
BioCentury | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...
BioCentury | Aug 17, 2019
Emerging Company Profile

Impact casting a wide synthetic lethality net

After laying the foundation with its PARP inhibitor, Impact plans to build a comprehensive synthetic lethality pipeline across known DNA damage repair targets and new ones outside of DDR to address a wider range of...
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
BioCentury | Feb 6, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Cell culture and mouse studies suggest the selective serotonin reuptake inhibitor (SSRI) clomipramine could help treat MS. Screening a library of oral generic drugs that cross the blood-brain barrier (BBB) in...
BioCentury | Jun 9, 2017
Company News

Genomic Vision and AstraZeneca collaborate to screen WEE1 inhibitors

AstraZeneca plc (LSE:AZN; NYSE:AZN) will use the FiberVision DNA molecular combing technology from Genomic Vision S.A. (Euronext:GV) to evaluate the impact of WEE1 tyrosine kinase (WEE1) inhibitors on DNA replication. The pharma hopes to develop...
BioCentury | Jun 8, 2017
Translation in Brief

Damage potential

Although cancer drugs have proven effective in treating autoimmune diseases, their intolerable long-term toxicity has discouraged new players from exploring their potential. A group at University of Cincinnati has discovered a new combination that kills...
BioCentury | May 19, 2016
Distillery Therapeutics

Therapeutics: Chondroitin sulfate proteoglycans (CSPG); versican (VCAN)

Autoimmune disease INDICATION: Multiple sclerosis (MS) In vitro and mouse studies identified a UDP-N-acetylglucosamine-based inhibitor of CSPG synthesis that could help treat MS. Chemical synthesis of UDP-N-acetylglucosamine analogs and testing in mouse and human astrocyte-based...
BioCentury | Dec 3, 2015
Distillery Therapeutics

Therapeutics: Interleukin-1 receptor-associated kinase 1 (IRAK1)

Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting IRAK1 could help treat triple-negative breast cancer (TNBC). IRAK1 levels were higher in tumor samples from patients with aggressive TNBC than from...
BioCentury | Jun 1, 2015
Clinical News

AZD1775: Phase II data

Data from 22 evaluable patients with p53-mutated refractory or resistant ovarian cancer in an open-label, Dutch Phase II trial showed that first-line treatment with twice-daily 225 mg oral AZD1775 for 2.5 days plus carboplatin led...
Items per page:
1 - 10 of 30